Assay | Thrombosis, n = 164 No. (% positive) | No Thrombosis, n = 162 No. (% positive) | OR 95% CI* | p (adjusted)* | |
---|---|---|---|---|---|
IgG | Anti-ß2-GPI | 18 (11) | 6 (4) | 3.3 (1.2, 8.9) | 0.021 |
Anti-ß2-GPI D1 | 11 (7) | 9 (6) | 1.1 (0.4, 2.9) | 0.79 | |
aCL | 22 (13) | 16 (10) | 1.4 (0.7, 2.9) | 0.34 | |
Anti-PS/PT | 26 (16) | 14 (9) | 2.2 (1.0, 4.8) | 0.045 | |
IgM | Anti-ß2-GPI | 8 (5) | 9 (6) | 0.8 (0.3, 2.3) | 0.69 |
aCL | 19 (12) | 14 (9) | 1.3 (0.6, 2.8) | 0.47 | |
Anti-PS/PT | 43 (26) | 25 (15) | 1.9 (1.1, 3.3) | 0.033 | |
IgA | Anti-ß2-GPI | 48 (29) | 24 (15) | 2.4 (1.3, 4.2) | 0.0028 |
aCL | 11 (7) | 1 (1) | 9.5 (1.2, 75.8) | 0.034 | |
Anti-ß2-GPI D4/5 | 35 (21) | 28 (17) | 1.3 (0.7, 2.3) | 0.38 | |
IgG/M | Anti-PS/PT | 38 (23) | 24 (15) | 1.7 (0.9, 3.1) | 0.087 |
LAC** | dRVVT | 52 (37) | 19 (13) | 3.8 (2.0, 7.3) | < 0.0001 |
↵* Adjusted for age, sex, and ethnicity.
↵** Forty-three patients did not have dilute Russell viper venom test (dRVVT) results available. Thus, the total number of patients for the thrombosis group was 44, and the no-thrombosis group, 239. Anti-ß2-GPI: anti-ß2-glycoprotein I; anti-ß2-GPI D1: anti-ß2-glycoprotein I domain 1; aCL: anticardiolipin; anti-PS/PT: antiphosphatidylserine/prothrombin; LAC: lupus anticoagulant; anti-ß2-GPI D4/5: anti-ß2-glycoprotein I domain 4/5.